Skip to main content
Journal ArticleOPEN ACCESS

Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature

Clinical Case Reports (2020) 8(12) 3043-3049
DOI: 10.1002/ccr3.3302
5Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed disease.

Author supplied keywords

Cite

CITATION STYLE

APA

Win, H., & Gowin, K. (2020). Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature. Clinical Case Reports, 8(12), 3043–3049. https://doi.org/10.1002/ccr3.3302

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free